Objectives: The aim of the study is to evaluate the efficacy and safety of DTMS for the treatment of PTSD.
Patient Population: 176 male and female subjects, 22-68 years of age, currently diagnosed with PTSD according to the DSM-V criteria.
Structure: A randomized, controlled, prospective, 9 week, double blind, multicenter study.
Blinding: The treatment administrator, study rater, all study personnel and patients will be blinded to the treatment being administered.
Concurrent Control: The study group will receive active DTMS treatment and the control group will receive inactive, sham treatment.
The purpose of this study is to determine if there are any differences in the improvement of MDD and PTSD symptoms when using two different types of ECT, and also to determine what effect recalling two different memories (a positive memory or negative PTSD memory) just prior to receiving ECT may have on PTSD symptoms. The two types of ECT treatment to be used in this study are called right unilateral ultrabrief (RUL UB) ECT and bilateral brief pulse (BL BP) ECT. Both types of ECT are widely used in the treatment of depression and are commonly used when ECT is recommended. This study will involve 70 (35 local and 35 at Long Beach VA site) subjects who are veterans suffering from MDD and PTSD.
We propose a randomized controlled clinical trial of 1,200 military service members who are at increased risk for suicide but not currently in behavioral health treatment. We are testing the effectiveness of a brief phone-based intervention aimed at changing military member's perceptions about behavioral health therapy. Participants will complete five interviews over the course of one year to collect information about change in behavioral health symptoms and treatment engagement.
The goal of this study is to receive Veteran feedback on an intervention being developed for female Veterans to reduce their risk of alcohol misuse and sexual assault. We are recruiting 20 female Veterans who engage in alcohol misuse to receive feedback on the intervention content. Feedback will be integrated into the intervention prior to being used with female Veterans.
As a result of sustained operations in Afghanistan and Iraq, there are an increasing number of U.S. military Veterans with substance use disorders and comorbid posttraumatic stress disorder (PTSD). If left untreated, individuals with substance use disorders and PTSD are at increased risk for developing other mental health problems (e.g., depression, anxiety), suicidal ideation and attempts, medical problems, reduced resiliency and military readiness, vocational problems, and family/social impairment.Determine the benefits of N-acetylcysteine (NAC) in treating alcohol use disorder and comorbid post-traumatic stress disorder (PTSD) among military Veterans.
In this study, we will evaluate the impact of the dietary supplement of krill oil concentrate, which contains the omega-3 HUFAs, on the success of U.S. Army officers training outcomes in Infantry Basic Officer Leadership Course (IBOLC) training Part I) and Ranger training (Part II). We are researching the effects on key performance measures from the two parts of their training, as well as underlying psychological and cognitive functioning that are components of success. The questions addressed by this study are:
1. Will treatment with krill oil concentrate containing the omega-3 HUFAs improve cognitive and psychiatric functioning during U.S. Army Infantry Basic Officer Leadership Course (Part I)?
2. Will treatment with krill oil concentrate containing the omega-3 HUFAs improve the performance of officers during portions of the U.S. Army Infantry Basic Officer Leadership Course (Part I) and Ranger training (Part II)? This phase will combine the cognitive and physiological challenges from which we measure performance outcomes.
3. Do effects of the supplements continue once a person stops taking them? Are there any group differences in functioning observed 2 months after treatment is discontinued (i.e., after Ranger training)?
A small sub-study will address the same questions among older, more experienced Army personnel in Part I only.
Walking is important to persons who have had a stroke and better rehabilitation methods are needed to restore or improve their walking. This project will investigate ways to improve upon and diagnose the specific underlying impairments. Future work will allow clinicians, such as physicians and physical therapists, to make measurements in their clinic to better diagnose a person?s specific walking deficit, design a specific treatment plan, and monitor its ability to restore or improve the person?s walking.
The purpose of this study is to evaluate the effects of a medication (doxazosin) on reducing symptoms of posttraumatic stress disorder (PTSD) and substance use in Veterans. We will also examine the effects of doxazosin on brain activity at pre and post treatment.
The aim of this study is to gather information about veterans at the Ralph H. Johnson Veterans Medical Center (RHJ-VAMC) who've experienced a stroke and are interested in participating in rehabilitation research.
VA principal investigators at the Center for Rehabilitation Research in Neurologic Conditions (CRRNC) conduct stroke rehabilitation research for individuals. CRRNC include laboratories that investigate and assess upper extremity motor function, neuro-stimulation, communication and swallowing, locomotor energetics, locomotor and rehabilitation, and motor performance functions.
Participants will be asked to come to the CRRNC located at the Medical University of South Carolina (77 President Street, Charleston, South Carolina) and fill out a simple screening form with study personnel. Participants may be contacted in the future for qualifying studies.
The 'dual burden' of (a) loss of a fellow service member in the context of (b) experiencing repeated extreme life threat is unique to military combat personnel and a core characteristic of combat-related Prolonged Grief Disorder (PGD), a disorder as prevalent as Post-traumatic stress disorder and associated with functional impairment, disability, and suicidality. Effective treatments for depression and PTSD have proven less than adequate in treating PGD when each is offered in isolation; and simply combining these 12-16 week treatment regimens into a 24-36 week treatments is not a viable approach, particularly with a population predisposed to avoiding extended mental health care. The proposed project addresses the need for a Veteran/ military specific treatment of PGD, and uses technology to deliver this treatment in a format that is far more likely to be accepted by military personnel and Veterans. This study will impact clinical practice by providing the first evidence for effective treatment PGD in Veterans.